As renal function declines, patients with chronic kidney disease (CKD) are subjected to a graded increase in rates of cardiovascular events [1]. Heart failure and sudden cardiac death account for a large proportion of these events, especially at advanced CKD stages [2], and are both linked to the development of a peculiar CKD related cardiac remodeling, termed as uremic cardiomyopathy (UC) [3,4]. UC is characterized by progressive left ventricular (LV) hypertrophy (LVH) [5], fibrosis [5,6] and myocardial edema [7], it is accompanied by mainly diastolic LV dysfunction [8], and it is associated with worse prognosis [9].
